Callisto Pharmaceuticals Adjourns Annual Stockholders Meeting Due to Lack of a Quorum

NEW YORK--(BUSINESS WIRE)-- Callisto Pharmaceuticals, Inc. (OTCBB: CLSP.OB), announced today that it adjourned its annual stockholders' meeting held on July 9, 2010 due to lack of a quorum. The agenda for the adjourned meeting and the record date for the stockholders entitled to vote at that meeting will be publicly announced in the next few weeks. The Company will also file a new proxy statement, which will be mailed to stockholders. The Company encourages all stockholders to participate in the next stockholder meeting.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused primarily on the development of Atiprimod, an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activity, to treat rheumatoid arthritis (RA). Atiprimod earlier completed a Phase II clinical trial in advanced carcinoid cancer, a neuroendocrine tumor, and, subsequent to this, further development was redirected towards treatment of RA. Callisto's second drug, L-Annamycin, is a member of the anthracycline family, with a novel therapeutic profile including activity against drug resistant tumors. L-Annamycin completed a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia patients. More information is available at http://www.callistopharma.com.



CONTACT:

Callisto Pharmaceuticals, Inc.
Gary S. Jacob, Ph.D., CEO, +1-212-297-0010
[email protected]
http://www.callistopharma.com

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.